Preventing Contamination: Aseptic Processing Risk Factors Richard L. Friedman, M.S. FDA/CDER 10/22/02 OPS Advisory Committee/ Aseptic Processing.

Slides:



Advertisements
Similar presentations
Environmental Monitoring Considerations
Advertisements

Microbiological Validation
WHO - PSM Air Handling Systems Heating Ventilation and Air Conditioning (HVAC) – Part 1 Pharmaceutical Quality, Good manufacturing Practice & Bioequivalence.
World Health Organization
1 Utility Systems Process Systems – ‘Direct Impact Systems’ Contact the Product Contact Materials that will Ultimately Become Part of the Product Could.
Heating Ventilation and Air Conditioning (HVAC) – Part 3
Sterile Drug Process Inspections
Facility Design and CGMP Considerations for Cell Therapy Products
Aseptic Pharmacy Compounding- Contemporary Issues and Challenges Shan Chikhale, Ph.D. Professor of Pharmacy South College of Tennessee, Inc. Knoxville,
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
9. Cleanroom Testing and Monitoring. Purposes for initial test: Fulfill the design –working correctly and achieving the contamination standards Bench-mark:
MCC PRESENTATION - GMP MANUFACTURING ENVIRONMENTS
External Defibrillators: Recalls, Inspections, and the Quality System Regulation Melissa Torres Office of Compliance December 15, 2010.
Objectives Objectives: Food safety management systems
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
World Health Organization
Qualification of HVAC systems
Food Safety Management Systems
MCC PRESENTATION - GMP MANUFACTURING ENVIRONMENTS
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Radiopharmaceutical Production
Process Simulation Media Fills
Advisory Committee for Pharmaceutical Science Sterilization Options Sterilization Options Kristen D. Evans Investigative Engineer, USFDA October 22, 2002.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Ashland Specialty Ingredients IFAC’s cGMP Audit Guide How the Food Ingredient Industry has Responded to FSMA and Food Safety Audits Priscilla Zawislak.
8-2 Food Safety Management Systems Food safety management system: Group of practices and procedures intended to prevent foodborne illness Actively controls.
Food Safety Management Systems
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Introduction to Equipment
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
Part 3: Design, qualification
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
Presented by Steven P. Feltman Food Safety and Quality Specialist.
World Health Organization
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Part I: Introduction and overview
Compounding Issues in Neuromodulation December 9, 2012 North American Neuromodulation Society 16 th Annual Scientific Meeting Wynn Hotel, Las Vegas Nevada.
Horizontal Laminar Air Flow Vertical Laminar Air Flow.
© Pharmaceutical Consultancy Services, All rights reserved. MEDIA FILLS Jaap Koster.
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
© Pharmaceutical Consultancy Services, All rights reserved. MEDIA FILLS Jaap Koster.
Important informations
Moderated By Eyal Rivlin Lev Hakongressim, Weizmann Science Park, Ness Ziona May 2008.
Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.
Draft Guidance for Industry: CGMPs for Phase 1 INDs Joseph C. Famulare, Director Division of Manufacturing & Product Quality Office of Compliance, CDER,
A Guide for Management. Overview Benefits of entity-level controls Nature of entity-level controls Types of entity-level controls, control objectives,
8-2 Service Objectives: Food safety management systems Active managerial control Hazard Analysis Critical Control point (HACCP)
Final Rule for Preventive Controls for Animal Food 1 THE FUTURE IS NOW.
FDA Preliminary Concept Paper Sterile Drug Products Produced by Aseptic Processing This presentation summarizes the content of PDA’s official position,
Pharmaceutical Quality Control & current Good Manufacturing Practice
Awareness Training: ‘HARPC’ for Food Safety Complimentary Presentation by Quality Systems Enhancement 1790 Wood Stock Road Roswell GA E. mail:
Environmental Control and Developing a Science-based Monitoring Program Richard L. Friedman, M.S. FDA/CDER.
Wyeth-Ayerst Pharmaceuticals1 CLEANING VALIDATION Microbial Monitoring Anthony M. Cundell Ph. D. Associate Director, QA Microbiological Development & Statistics.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
Sterile Products Lab PHT 434
USP <1116> and its impact on Microbiology
Pharmaceutical Quality Control & current Good Manufacturing Practice
Author: Nurul Azyyati Sabri
Quality Control and Assurance
FDA Guide To Aseptic Processing
Application of rapid methods for the risk assessment of pharmaceutical processes Tim Sandle, Ph.D.
Pharmaceutical Quality Control & current Good Manufacturing Practice
II. 4 Quality risk management as part of…
Sterile Products Lab PHT 434
Aseptic Processing 2019: Trends and Challenges
Pharmaceutical Quality System in regard to Good Engineering Practice
Manufacture of Sterile Medicinal Products: Practical Examples
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Presentation transcript:

Preventing Contamination: Aseptic Processing Risk Factors Richard L. Friedman, M.S. FDA/CDER 10/22/02 OPS Advisory Committee/ Aseptic Processing

TOPICS Risk-based approach Risk-based approach Critical Control Points (CCPs) Critical Control Points (CCPs) –Sources of Variability –Holistic Facility Case studies Case studies –Recurring problems underscore importance of CCPs Latitude & Innovation Latitude & Innovation –New Technology, Automation, Facility Improvements Five Major Issues for Discussion Five Major Issues for Discussion

Risk Analysis – FMEA Reducing Risk Severity Factor: “Process changes or product redesign…” including “development of an aseptically produced product into one with terminal sterilization.” “Process changes or product redesign…” including “development of an aseptically produced product into one with terminal sterilization.” Reducing Probability of Occurrence of Risk: “Process automation projects, tighter controls upstream in the process, and new technologies such as isolators” “Process automation projects, tighter controls upstream in the process, and new technologies such as isolators” Probability of Detecting Failures: Validation is “intensified monitoring which should detect flaws or weaknesses, which may not be normally observable. A media fill is a good example of a validation test.” Validation is “intensified monitoring which should detect flaws or weaknesses, which may not be normally observable. A media fill is a good example of a validation test.” [Noble, P., PDA Journal of Pharmaceutical Science and Technology, July/August 2001.]

Risk-Based Approach Critical Control Points Causes of Contamination Causes of Contamination –Where are the potential routes of contamination in an aseptic process? Detection of Contamination Problem Detection of Contamination Problem –What measurements are most valuable in indicating sterility assurance? Focus on issues of concern Focus on issues of concern –Influential factors that determine control of the facility and process –Failure to meet CGMP can impact safety or efficacy

D= Design M= Maintenance Daily “Sterility Assurance” Media Fills Aseptic Processing Line D/M Response to Deviations & Environmental Control Trends Disinfection Procedures & Practices QA/QC Facility & Room D/M Process -personnel flow -material flow -layout Personnel HVAC/ Utilities

Risk-Based Approach Design Aseptic Processing requires “A strict design regime, not only on the process area, but on the interactions with surrounding areas and the movement of people, materials and equipment so as not to compromise the aseptic conditions.” [ISPE Sterile Manufacturing Facilities Guide, Volume 3, January 1999]

Personnel “Continued vigilance throughout the entire manufacturing process” “Continued vigilance throughout the entire manufacturing process” [Avis, K.,“Personnel – An academic Approach,” PDA Journal, Sept-Oct., 1971] “Unstable situations are, in most cases, caused by the influence of arms and hands.” “Unstable situations are, in most cases, caused by the influence of arms and hands.” [Ljungqvist, B., and Reinmuller, B., Clean Room Design: Minimizing Contamination Through Proper Design; Interpharm Press, 1997]

Environment Studies have shown that “the level of airborne microorganisms in the filling environment has a profound effect on the level of product contamination.” Studies have shown that “the level of airborne microorganisms in the filling environment has a profound effect on the level of product contamination.” [Ljungqvist, B., and Reinmuller, B., Clean Room Design: Minimizing Contamination Through Proper Design; Interpharm Press, 1997] Researchers found a “definable direct relationship between the fraction of product contaminated and the level of microorganisms in the air surrounding the machine” [Sinclair, C.S., and Tallentire, A., J Pharm Sci Tech, 49 (6), ] Researchers found a “definable direct relationship between the fraction of product contaminated and the level of microorganisms in the air surrounding the machine” [Sinclair, C.S., and Tallentire, A., J Pharm Sci Tech, 49 (6), ]

DESIGN & ENVIRONMENTAL CONTROL: Sterility Link DESIGN & ENVIRONMENTAL CONTROL: Sterility Link BFS Air Shower Setting Air Velocity (m s -1 ) Fraction Contaminated Configuration A Challenge Concentration 5 x 10 4 spores m -3    

Environmental Data and State of Line Qualification Environmental Data and State of Line Qualification “It also may be necessary to requalify with acceptable process simulation tests in response to adverse trends or failures in the ongoing monitoring of the facility or process such as: Continued critical area EM results above action/alert limits…” “It also may be necessary to requalify with acceptable process simulation tests in response to adverse trends or failures in the ongoing monitoring of the facility or process such as: Continued critical area EM results above action/alert limits…” [PDA Technical Report #22 “Process Simulation Testing for Aseptically Filled Products,” 1996] “ Facility and equipment modification, significant changes in personnel, anomalies in environmental testing results and end product sterility testing showing contaminated products may all be cause for revalidating the system.” “ Facility and equipment modification, significant changes in personnel, anomalies in environmental testing results and end product sterility testing showing contaminated products may all be cause for revalidating the system.” [FDA’s 1987 “Guideline on Sterile Drug Products Produced by Aseptic Processing”]

Design, Environment, & Personnel: Link to Sterility Widely accepted that each of the following is crucial to assuring sterility: Widely accepted that each of the following is crucial to assuring sterility:DesignEnvironmentPersonnel That’s theory, what about actual experiences? That’s theory, what about actual experiences?  The above principle plays out in the many case studies we see throughout each year.  Lack of adherence to CGMP in these areas underlies the vast number of failures in the industry.

Case Study Media Fill Failure Media Fill Failure: Media Fill Failure: –Approx. 60% contaminated –Considered spurious. Corrections made to firm’s satisfaction. FDA Guideline (and PDA #22): 3 Lots for Revalidation FDA Guideline (and PDA #22): 3 Lots for Revalidation –First Media Fill Batch = No contamination –Second Media Fill Batch = Over 95% contaminated (over 5000 vials) –Third Media Fill Batch = No contamination If one batch was run, a firm would return to production/release of commercial lots without knowledge non-sterility problem still existed. If one batch was run, a firm would return to production/release of commercial lots without knowledge non-sterility problem still existed. Root Cause: Root Cause: –Personnel / Aseptic Connection Isolates in both failures were common skin-borne microbes Isolates in both failures were common skin-borne microbes Only Partially Gowned, Skin Exposed, Aseptic Technique questionable. Only Partially Gowned, Skin Exposed, Aseptic Technique questionable. Corrections to resolve these issues: Full sterile gown donned and enhanced personnel/environmental monitoring performed in near term. Equipment later modified to allow for SIP. Corrections to resolve these issues: Full sterile gown donned and enhanced personnel/environmental monitoring performed in near term. Equipment later modified to allow for SIP.

Case Study Sterility Failures and Environmental Trend Management failed to require follow-up on sterility failures with both mold and bacterial contaminants. Batches were released upon re-testing, with each of these failures attributed to inadvertent contamination while performing the sterility test. There was little or no data to support these conclusions. Investigations failed to adequately address possible manufacturing causes (e.g., microorganism correlation). Mold was found on multiple occasions in cleanrooms, and these mold detections exceeded established cleanroom action levels. Management failed to require follow-up on sterility failures with both mold and bacterial contaminants. Batches were released upon re-testing, with each of these failures attributed to inadvertent contamination while performing the sterility test. There was little or no data to support these conclusions. Investigations failed to adequately address possible manufacturing causes (e.g., microorganism correlation). Mold was found on multiple occasions in cleanrooms, and these mold detections exceeded established cleanroom action levels.

Sources of Contamination: Investigation Conclusions (e.g.) Aseptic practices: Aseptic practices:  Personnel returned after long winter shutdown  Operator reached over open vials to remove fallen vial on line with gloved hands  Poor personnel flow Poor aseptic connections Poor aseptic connections Poor Sanitization: Procedures deficient, or poorly executed Poor Sanitization: Procedures deficient, or poorly executed Construction in another room on the same floor caused increased airborne contamination (sporeforming bacteria) in facility Construction in another room on the same floor caused increased airborne contamination (sporeforming bacteria) in facility Poor gown design: Introduced new gown component, but then found it was contamination source Poor gown design: Introduced new gown component, but then found it was contamination source

Sources of Contamination: Investigation Conclusions (e.g.) New line’s HVAC installation: Approved as qualified, but media fill demonstrated inadequate HEPA seal (over 90% vials contaminated) New line’s HVAC installation: Approved as qualified, but media fill demonstrated inadequate HEPA seal (over 90% vials contaminated) Velocity through HEPA Filters: Variable velocities between filters. Inadequate laminar flow resulted. Low or undetectable velocity at work surface. Had monitored volume thru filter but did not detect problem. Media Fill: 11 positives in approximately 18,000 vials. Velocity through HEPA Filters: Variable velocities between filters. Inadequate laminar flow resulted. Low or undetectable velocity at work surface. Had monitored volume thru filter but did not detect problem. Media Fill: 11 positives in approximately 18,000 vials. Mechanical failure of filling tank; main pump failure; cooling system leaks at joints/pinholes. Mechanical failure of filling tank; main pump failure; cooling system leaks at joints/pinholes.

Five Topics for Discussion Sterilization Options Sterilization Options Aseptic Processing Design, Evaluation and Contamination Prevention Aseptic Processing Design, Evaluation and Contamination Prevention Media Fills Media Fills Environmental Monitoring Environmental Monitoring Personnel Issues Personnel Issues

CGMPs in the 21 st Century Science and Innovation New technology, automation, facility improvements. Concept paper acknowledges advantages of: Reducing direct personnel involvement in aseptic operations through isolation technology and barrier concepts Well-conceived design (e.g., airlocks) Advantage: Increased automation Liberalizing some old standards e.g., velocity (FPM) setting Latitude: e.g., BFS microbial standards stressed over particulate levels Firms who follow sound CGMP operating procedures and have defined good process metrics will benefit most

Summary We’ve been listening We’ve been listening Risk-based Approach Risk-based Approach –Emphasis on product risk areas –CGMP systems should detect trends before there is a product contamination consequence Theoretical and practical basis Theoretical and practical basis We look forward to your comments! We look forward to your comments!